Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax Registry
- Status
- RECRUITING
- Phase
- N/A
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Expanded Access to Navitoclax
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3